
Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH
Mar 12, 2025
Raichur (Karnataka) [India], March 12: Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug (IND) - Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg - and recommended marketing authorization for treating non-alcoholic fatty liver disease (NAFLD).
Read More ..